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Abstract The human H19 gene is a paternally imprinted
oncofetal gene, highly expressed in several fetal tissues, down-
regulated in nearly all adult tissues but re-expressed in
carcinomas of tissues which express the gene in fetal life. It
has no known protein product and till today, no function could be
designated to H19 RNA. Cells derived from bladder carcinomas
and hepatocellular carcinomas were transfected with plasmids
carrying a luciferase reporter gene under the control of a 800
nucleotides long promoter region of the H19 gene either alone or
together with different parts of a 5 kb downstream region,
previously shown to possess enhancer activity. Our results
provide evidence that three regions of the 3P downstream
sequence can independently stimulate the H19 promoter activity
in a tissue and cell specific manner. The growth rate of two cell
populations, both derived from the same bladder carcinoma cell
line and which differ in their H19 RNA content, were compared.
The cells with a high H19 RNA level stopped their proliferation
after 48 h when cultivated in a low serum containing media while
the cells lacking H19 RNA continued their proliferation for at
least an additional 48 h period.
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1. Introduction
The human H19 gene is located on chromosome 11p15.5. It
is one of a cluster of at least seven imprinted genes, six of
them are expressed from the maternally inherited allele, the
only exception is the paternally expressed IGF-2 gene [1].
The H19 gene encodes a polyadenylated transcript which is
transported to the cytoplasm. Recently, it was reported that
H19 RNA is associated with polyribosomes in di¡erent hu-
man cells [2]. However, no protein product of the H19 gene
has been detected till now and the 256 amino acid long pro-
tein, the potential product of the open reading frame of the
human H19 gene, does not share any amino acid sequence
homology with the potential protein products of the mouse
and rat H19 open reading frames [3]. Notwithstanding its very
high abundance in some tissues, we are still ignorant about its
functions.
Upon the basis of several experimental ¢ndings, a role as
tumor suppressor has been proposed for the H19 gene [4^6].
However, recently, we and others have reported ¢ndings that
are contradictory to such a proposal. The H19 gene was
found to behave as an oncofetal gene, a gene highly expressed
in embryonic tissues, not or very low expressed in tissues of
the normal adult, but expressed in tumors derived from tissues
which expressed the gene during embryonic development [7^
9]. We injected cells from human bladder carcinoma and cho-
riocarcinoma cell lines, which did not express H19, into nude
mice. In the tumors which developed, H19 was expressed at
an easily detectable level [10^12]. The signi¢cant increase in
H19 expression during the process of tumor formation in the
mice raises the question if the H19 gene product ful¢lls a role
in the process of tumorigenesis.
In order to answer this question, we stably transfected cells
from a bladder carcinoma cell line, which did not express
H19, either with an episomal construct in which H19 expres-
sion is under the control of the CMV promoter, known to be
highly active in cell lines derived from human bladder carci-
noma, or with a similar construct not expressing the H19
gene.
In the experiments described, we showed a very signi¢cant
di¡erence in the response of the cells to a low serum content
of the growth medium. The H19 RNA containing cells
stopped their proliferation after 48 h in contrast to the cells
lacking H19 RNA.
In a recent work, we reported that in cells of the chorio-
carcinoma-derived cell lines JAr and JEG-3, the transcription
of the human H19 gene is under the control of a 5 kb long 3P
downstream enhancer region [13]. Similar results were previ-
ously reported for the mouse gene by Yoo-Warren et al. [14].
We have extended our investigation on this 5 kb enhancer
region and have sequenced the whole 5 kb region mentioned
above and studied its action on the H19 promoter in human
bladder carcinoma cell lines. In order to study the sequences
responsible for the enhancer e¡ect in greater detail, we report
here about the enhancer activity of di¡erent parts of the
above mentioned 5 kb region. These experiments were carried
out using the highly sensitive luciferase reporter gene assays.
The results obtained provide evidence that the human H19
5 kb 3P downstream enhancer region contains three sequence
motifs which can independently stimulate transcription from
the H19 promoter.
2. Materials and methods
Human bladder carcinoma cell lines HT-1376, UM-UC-3, T24P,
5637, RT-112 and hepatocellular carcinoma cell lines Huh7 and
Hep3B were obtained from the American Type Culture Collection,
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USA. The EJ28 cell line was obtained from the German Cancer Re-
search Center (Heidelberg, Germany). The cells were grown as pre-
viously described [13].
For measurements of the cell culture growth rate, the cells were
seeded at an initial density of 0.2U106 cells into dishes, harvested
after designated periods of time and counted. Cells were grown at
di¡erent FCS concentrations, as indicated in legends.
Preparation of probes for detection of sense and antisense H19
RNA and Northern blotting was carried out as described in [13].
2.1. Luciferase reporter gene constructs
All the luciferase gene reporter constructs were built from the pGL3
basic (Luc-1) vector (Promega) which lacks both eukaryotic promoter
and enhancer sequences. The H19 promoter cloned in the EcoRV site
of the pBluescript II SK (designed pbh 19 p#1) was obtained from Dr
Ekkehard Schulze. The H19 promoter region from nucleotide 3819 to
+14 was ampli¢ed by PCR from the pbh 19 p#1, using primers
5P-ATATGGTACCGACAACCCTCACCAAAG-3P (upstream) and
5P-ATATAAGCTTCTTCTCCCTCACCCTGCTC-3P (downstream).
In order to facilitate subsequent cloning of the PCR product, KpnI
and HindIII enzyme restriction sites were incorporated into the PCR
primers design. The resulting PCR product was digested with the KpnI
and HindIII enzymes and ligated into the KpnI and HindIII sites of
the Luc-1 basic vector, yielding the Luc-PBH19 construct.
Reporter gene plasmids containing di¡erent H19 enhancer regions
downstream of the H19 promoter-Luc reporter gene were constructed
as follows. The plasmid PH19EH19D (described in [13]) containing
the 5 kb H19 downstream enhancer was digested with BamHI yielding
two fragments, a 4.1 kb fragment at the 5P end and an 0.9 kb frag-
ment at the 3P end of the 5 kb region.
The Luc-PBH19-4EH19 and the LucPBH19-0.9EH19 constructs
were prepared by insertion of the 4.1 kb and the 0.9 kb BamHI frag-
ments, respectively, into the BamHI site of Luc-PBH19 plasmid,
downstream to the H19 promoter/Luc reporter gene. The sequence
of the 4.1 kb fragment shows the presence of two BSTXI restriction
sites (at nucleotides 1206 and 3334), the construct Luc-PBH19-4EH19
was digested with BSTXI deleting a fragment between nucleotides
1206 and 3334 of the 4.1 kb region. Following self-ligation of the
plasmid, the expression vector Luc-PBH19-2EH19, which contains a
2 kb H19 fragment, was formed.
The plasmid PH19EH19D was digested with SacI, releasing the
5.0 kb H19 enhancer fragment. This enhancer and the linearized
plasmid Luc-1 were both converted to a blunt end terminus by T4
DNA polymerase, followed by ligation yielding the Luc-PBH19-
5EH19 construct.
2.2. H19 expression construct
A H19 expression vector was constructed as follows: a 6 kb frag-
ment of the human H19 [6] was cloned into the multiple cloning sites
of the pBKC-BKV (Genetech) episomal expression vector under the
control of the CMV promoter. The 6 kb H19 fragment spans the
complete transcribed region of the human H19 gene and begins
48 nucleotides upstream of the transcriptional start site. An 800 nu-
cleotides fragment derived from the 3P portion of the transcribed
region of the human H19 gene [13] was inserted in the pBKC-BKV
vector in an antisense orientation, providing us with a pBKC-BKV
non-H19 expression control construct (see Fig. 1). The pBKC-BKV
vector contains the gene for G418 resistance.
2.3. Transfections
Transient transfections were carried out as previously described
[13].
In the case of stable transfections of the T24P cells, 24 h after the
transfections with the pBKC-BKV episomal vectors, 0.5 mg/ml G418
(Geneticin) was added to 1.0 ml of the culture to initiate selection.
2.4. Luciferase assay
Cells carrying the reporter gene construct were harvested after 48 h
(20^100 Wg) and equal amounts of protein were examined for lucifer-
ase activity using the Promega kit, ‘Luciferase Assay System’ (E1500-
PROMEGA, USA). The light output was detected by the Lumac
Biocounter apparatus.
2.5. Sequencing
Sequencing was carried out on both strands of the DNA, using the
Automated DNA sequencing, Ye terminator cycle sequencing proce-
dure (ABT Prism 379, Perkin Elmer) DNA sequencer.
3. Results
We sequenced a 5.0 kb 3P downstream region of the human
H19 gene which was kindly donated to us by Dr S.M. Tilgh-
man (Princeton University, USA). The sequence of a 4.1 kb
long fragment starting at the 5P end of this region was sub-
mitted to GenBank (accession number AF091107). Recently,
the sequence of a 41 kb long region of human chromosome
11p15.5 was reported by Ishihara et al., GenBank accession
number AF087017 [15]. This sequence covered the H19 gene
region from nucleotide 38325 till +29 571. The sequence of
the 5.0 kb fragment that we determined was nearly 100%
identical to the corresponding sequence reported by Ishihara
et al. [15]. These data enabled us to accurately locate the 5.0
kb enhancer region used in our experiments, relatively to the
transcribed region of the H19 gene (from nucleotide 6033 till
+10 972).
In a previous communication [13], we reported that in cells
derived from human choriocarcinomas, the activity of the
Fig. 1. Expression of the H19 gene in T24P and transfected T24P
cells. Autoradiogram of Northern blots containing RNA isolated
from T24P cells (lane 1), T24P cells containing the non-H19 ex-
pressing episomal vector (TA11, TA12 and TA13, lanes 2^4) and
T24P cells containing a H19 expressing episomal vector (TA31,
TA32 and TA33, lanes 5^7). A second autoradiogram was pro-
duced, using sense H19 RNA as probe. No antisense RNA was de-
tected in any of the cell populations (results not shown).
Table 1
Stimulatory e¡ect of di¡erent H19 3P downstream regions on the
H19 promoter activity in bladder carcinoma-derived cells
Cell line H19 3P downstream regions in the luciferase
reporter gene construct
0.9 kb 4.1 kb 5.0 kb 2.0 kb
T24P 1.5 9.0 5.3 4.0
RT112 1.0 12 7.0 2.5
5637 11 4.4 15 2.0
EJ28 1.7 6.0 4.0 2.5
HT1376 17 20 32 20
UM-UC-3 9.0 7.0 10 1.1
In all luciferase gene constructs, a H19 promoter region preceded
the luciferase gene (see Section 2). The activity of the di¡erent H19
3P downstream regions in each cell line are calculated on the basis
of activity = 1.0 for luciferase activity of the construct in which the
reporter gene was under control of the H19 promoter alone.
Table 2
Stimulatory e¡ect of di¡erent H19 3P downstream regions on H19
promoter activity in hepatocellular carcinoma-derived cell lines
Cell line H19 3P downstream region in the luciferase
reporter gene construct
0.9 kb 4.1 kb 5.0 kb 2.0 kb
Huh7 1.0 13 13 4.0
Hep3B 1.0 45 38 8.0
Details as in Table 1.
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H19 promoter is stimulated by (a) sequence(s) in a 5.0 kb H19
3P downstream region. This region is located from nucleotide
+6033 till +10 972 relative to the H19 transcriptional start
sign. Moreover, we showed that this region also mediates
the induction of H19 gene expression in cell lines derived
from human testicular germ cell tumors by retinoic acid [13].
The results summarized in Table 1 show that the same 3P
downstream region can activate the H19 promoter in cells of
six bladder carcinoma cell lines. The 5.0 kb region was cut
into two non-overlapping fragments, one of 0.9 kb and one of
4.1 kb. The 4.1 kb fragment, when incorporated into a lucif-
erase reporter gene construct in which transcription of the
luciferase gene is under the control of the H19 promoter,
stimulated luciferase gene transcription in cells of all the six
cell lines tested (Table 1). The 0.9 kb fragment strongly en-
hances H19 promoter activity in three of the six cell lines, but
had only a small stimulatory e¡ect in two cell lines and no
activity at all in one of the cell lines (Table 1). In cell lines in
which the 0.9 kb fragment has a large enhancing e¡ect on
activity of the H19 promoter, the e¡ect of the 4.1 kb fragment
was signi¢cantly smaller than that of the 5.0 kb fragment.
Opposite results were obtained in those cells in which the
e¡ect of the 0.9 kb fragment was marginal or absent. The
2.0 kb fragment increased the activity of the H19 promoter
in cells of ¢ve cell lines but its e¡ect was smaller than that of
the 4.1 kb region. In one cell line, we did not observe any
stimulatory e¡ect.
We repeated the experiments with cells from two cell lines
derived from human hepatocellular carcinoma (Table 2). We
found no activity of the 0.9 kb region, the 4.1 and 5.0 kb
regions had the same or nearly the same stimulatory e¡ect
on the H19 promoter activity and the 2.0 kb region had a
smaller e¡ect than both the 4.1 and 5.0 kb regions.
In order to gain more information about the function of the
H19 gene product in the cell, we stably transfected cells of the
T24P bladder carcinoma cell line with either an H19 expres-
sion construct or a similar construct not expressing the H19
gene (see Section 2). Fig. 1 shows the level of H19 RNA in
those cells and in untransfected T24P cells.
We measured the growth rate of the above mentioned cells.
The cells were cultivated in two di¡erent media, one contain-
ing 10% FCS and the other 0.1% FCS. At the high FCS
concentration, transfected cells and the T24P parent cells
grew at approximately the same rate during a 4 day culture
period (Fig. 2). However, the cells transfected with the H19
expression construct grew much slower in 0.1% FCS contain-
ing medium than the cells containing non-H19 expression
constructs or the parent T24P cells. Actually, their prolifera-
tion was nearly completely inhibited after 48 h of culture (Fig.
2). We wish to emphasize here that the same results as shown
in Fig. 2 were obtained in six independent experiments, start-
ing from establishment of the stably transfected T24P cell
lines. The H19 RNA level in cells expressing H19 from the
expressing vector and grown in a 10% FCS containing me-
dium was equal to that of cells grown in 0.1% FCS containing
medium (Fig. 3).
Similar results were obtained using NCCIT cells, a cell line
derived from a Testicular Germ Cell Tumor, transfected with
the same episomal constructs as used in the above described
experiments. In these cells, H19 RNA could be detected only
in NCCIT cells transfected with the H19 expressing construct
(results not shown).
4. Discussion
All our observations summarized in Tables 1 and 2 indicate
the presence of at least three di¡erent enhancer elements in
the 5 kb 3P downstream region of the human H19 gene.
However, the capacity of these enhancer elements to acti-
vate the H19 promoter seems not only to be tissue speci¢c but
also to di¡er among cell lines derived from carcinomas of the
same tissue.
One of those enhancer elements, the one located in the
middle of the 4.1 kb fragments, was found to be active in
all cell lines tested. A second enhancer element, contained in
the 0.9 kb region, was not active in the two cell lines derived
from hepatocellular carcinomas and in one of the bladder
carcinoma-derived cell lines.
A third enhancer element located in the 3P region of the 4.1
kb fragment (and included in the 2.0 kb fragment) was active
in all (except one) of the cell lines tested.
Yoo-Warren et al. [14] found in the mouse H19 3P down-
stream region at least two separate enhancer elements. One of
them is contained in a 269 nucleotides fragment located be-
Fig. 2. Growth rates of T24P cells and T24P cells transfected with a
H19 expression episomal construct (TA31 and TA32) or with a con-
trol episomal construct (TA11 and TA12). (A) Cells grown in me-
dium containing 10% FCS. (B) Cells grown in medium containing
0.1% FCS. (1) T24P untransfected cells, (2) TA11 cells, (3) TA12
cells, (4) TA31 cells, (5) TA32 cells
Fig. 3. Expression of the H19 gene in T24P and transfected T24P
cells grown at di¡erent FCS concentrations. Cells were grown for
4 days in 0.1 or 10% FCS and H19 expression was examined in
Northern blots. For TA11 and TA31, see legend Fig. 2.
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tween +8 and +9 kb, relative to the H19 gene transcriptional
start site, the second is 700 nucleotides further downstream
and is contained in a 297 nucleotides fragment. We found two
regions in the 4.1 kb fragment of the human H19 gene used in
our experiments which bear a high percentage of sequence
identity with these two mouse enhancer regions. The ¢rst is
a 189 nucleotides fragment (between nucleotides +7658 and
+7847) with a 70% sequence identity with one of the mouse
enhancers. A second region is located between nucleotides
+9375 and 9674 with a sequence 78% identical to the second
mouse enhancer region. This fragment is also contained in our
2.0 kb fragment. This conservation of synteny supports our
assumption about the presence of two enhancer sequences in
the 4.1 kb region, one located in the middle, the second in the
3P end of this region.
In our present investigation, we have compared the growth
rate of two cell populations, both derived from the T24P
bladder carcinoma cell line, one expressing the H19 gene
and the second containing neither sense nor antisense H19
RNA. We observed a very signi¢cant di¡erence between
growth rates of cells containing H19 RNA and those of cells
lacking H19 RNA (Fig. 2). We assume that H19 RNA pre-
vents the cell from continuing proliferation under unfavorable
conditions, namely the lack of one or more growth factor(s)
obligatory for normal proliferation. It helps cells to avoid
growth under unfavorable conditions, the lack of serum fac-
tors, which will ultimately lead to cell death. Probably, H19
RNA can promote expression of genes which limit the growth
rate under certain stress conditions such as lack of one or
more serum factors. It is known that expansion of primary
tumors and metastases is critically dependent upon an ad-
equate supply of serum factors. As a result, both are highly
dependent upon neovascularization [16]. If our assumption is
true, then, H19 RNA itself plays an important role in the
regulation of tumor cell growth under physiological condi-
tions, namely temporary lack of an adequate supply of serum
factors.
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